PFIZER2024-10-012024-12-31 PFIZER2024-10-012024-12-31 PFIZER2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member PFIZER2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member PFIZER2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500680 PFIZER NA Pfizer Limited Equity 2024-04-01 2025-03-31 2025-01-31 2025-01-24 INR Crores Third quarter 14:30:00 16:00:00 2025-01-31 2025-01-31 Not applicable Single segment Pharmaceuticals 2024-10-01 2024-12-31 Unaudited Standalone 5379900000.00 427600000.00 5807500000.00 673100000.00 1049900000.00 242600000.00 962900000.00 15100000.00 148000000.00 991500000.00 4083100000.00 1724400000.00 0.00 1724400000.00 501000000.00 -52600000.00 448400000.00 0.00 1276000000.00 0.00 0.00 0.00 0.00 1276000000.00 -5400000.00 1270600000.00 0.00 0.00 457500000.00 10 27.89 27.89 0.00 0.00 27.89 27.89 1.The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on January 31, 2025. 2.The standalone financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). 3.The Company does not have any subsidiary company or associate company or joint venture company as at December 31, 2024. 4.The financial results for the quarter and nine months ended December 31, 2024 have been subject to Limited Review by the Statutory Auditors of the Company. The Limited Review report does not contain any modifications. The Limited Review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerltd.co.in 5.Exceptional item for the quarter and nine months ended December 31, 2023 and year ended March 31, 2024 is in relation to provision for old pending VAT / CST litigations. The Company opted for Maharashtra VAT Amnesty Scheme for certain years and had received final settlement orders. Pursuant to the said orders, the Company had written back excess provision of Rs.7.95 crore. 6.The Company had intended to transfer its unexpired leasehold rights in the Maharashtra Industrial Development Corporation (“MIDC”) Land and Sale of Buildings constructed on such land at Thane and accordingly, it was classified as ‘Asset held for sale’. During the quarter ended December 31, 2023, the Company had entered into an Agreement to Assign and Assume the Lease of MIDC Land and Sale of Buildings constructed on such land to Zoetis Pharmaceutical Research Private Limited, for a lumpsum consideration of Rs. 264.40 crore, of which Rs. 52.88 crore was received as an advance. During the quarter ended December 31, 2024, the Company has received a direction from MIDC to pay charges towards transfer and to comply with certain conditions. Completion of transaction is subject to the final approval from MIDC and hence effect of the said agreement has not been given in these financial results. 7.The Company has only one segment which is ‘Pharmaceuticals’. Therefore, disclosure relating to segments is not applicable and accordingly not made. Single segment 2024-04-01 2024-12-31 Unaudited Standalone 16894400000.00 1276700000.00 18171100000.00 2017000000.00 3732300000.00 330400000.00 2884200000.00 57200000.00 443900000.00 2803200000.00 12268200000.00 5902900000.00 0.00 5902900000.00 1650400000.00 -114100000.00 1536300000.00 0.00 4366600000.00 0.00 0.00 0.00 0.00 4366600000.00 -16100000.00 4350500000.00 0.00 0.00 457500000.00 10 95.44 95.44 0.00 0.00 95.44 95.44 Other Expenses 991500000.00 Other Expenses 2803200000.00 -7200000.00 -21500000.00 -1800000.00 -5400000.00